ScinoPharm Taiwan Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	3,265	3,110	4,166	3,942	4,295	4,081
Cash & Short-Term Investments	3,265	3,110	4,166	3,942	4,295	4,081
Cash Growth	5.41%	-25.35%	5.70%	-8.22%	5.24%	0.64%
Accounts Receivable	500.96	612.41	633.62	788.22	635.26	360.25
Other Receivables	23.56	11.62	20.57	25.23	18.28	32.8
Receivables	524.52	624.03	654.19	813.45	653.55	393.04
Inventory	1,791	1,637	1,673	1,512	1,189	1,345
Prepaid Expenses	144.06	119.99	114.91	105.79	132.24	96.85
Other Current Assets	-	0.09	-	8.3	51.13	50.71
Total Current Assets	5,725	5,491	6,608	6,381	6,320	5,967
Property, Plant & Equipment	4,202	4,083	4,426	4,399	4,498	4,648
Long-Term Investments	1,093	1,368	70.13	69.97	112.62	185.8
Other Intangible Assets	14.62	15.36	17.13	19.15	9.95	8.79
Long-Term Deferred Tax Assets	679.54	664.63	625.26	640.93	637.44	614.98
Other Long-Term Assets	146.06	236.22	196.6	211.48	332.96	267.07
Total Assets	11,860	11,858	11,943	11,722	11,911	11,691
Accounts Payable	154.56	62.53	82.17	102.46	126.5	70.86
Accrued Expenses	-	105.53	143.45	139.78	139.6	124.62
Short-Term Debt	169.95	130.42	35.56	32.14	77.6	-
Current Portion of Leases	24.66	23.46	19.64	17.56	17.89	16.17
Current Income Taxes Payable	27.22	14.5	11.5	62.6	99.64	71.17
Current Unearned Revenue	192.9	115.35	119.4	110.97	67.75	70.57
Other Current Liabilities	304.25	258.05	355.97	263.96	274.12	202.93
Total Current Liabilities	873.54	709.84	767.68	729.45	803.09	556.31
Long-Term Leases	667.5	608.78	620.34	570.23	581.18	540.27
Pension & Post-Retirement Benefits	-	10.69	23.61	54.51	74.49	79.55
Long-Term Deferred Tax Liabilities	1.46	0.63	1.3	1.66	-	0.35
Other Long-Term Liabilities	4.82	3.05	3.99	1.3	2.36	3.65
Total Liabilities	1,547	1,333	1,417	1,357	1,461	1,180
Common Stock	7,907	7,907	7,907	7,907	7,907	7,907
Additional Paid-In Capital	1,295	1,295	1,295	1,295	1,295	1,295
Retained Earnings	1,327	1,310	1,450	1,348	1,346	1,370
Comprehensive Income & Other	-216.11	12.32	-126.18	-185.86	-98.18	-61.13
Shareholders' Equity	10,313	10,525	10,526	10,364	10,450	10,511
Total Liabilities & Equity	11,860	11,858	11,943	11,722	11,911	11,691
Total Debt	862.11	762.66	675.54	619.92	676.67	556.43
Net Cash (Debt)	2,403	2,347	3,490	3,322	3,618	3,524
Net Cash Growth	0.10%	-32.75%	5.08%	-8.19%	2.65%	1.31%
Net Cash Per Share	3.04	2.96	4.40	4.19	4.56	4.45
Filing Date Shares Outstanding	790.74	790.74	790.74	790.74	790.74	790.74
Total Common Shares Outstanding	790.74	790.74	790.74	790.74	790.74	790.74
Working Capital	4,852	4,781	5,840	5,651	5,517	5,410
Book Value Per Share	13.04	13.31	13.31	13.11	13.22	13.29
Tangible Book Value	10,298	10,509	10,509	10,345	10,440	10,502
Tangible Book Value Per Share	13.02	13.29	13.29	13.08	13.20	13.28
Buildings	-	4,318	4,309	4,249	4,095	3,546
Machinery	-	6,862	6,647	6,432	6,249	5,641
Construction In Progress	-	52.08	194.04	77.72	155.62	1,119

Source: S&P Global Market Intelligence. Standard template. Financial Sources.